Answers are grounded in this paper and cite their sources.
This review discusses ribosome inactivating proteins like MAP30 and their anti-HIV and anti-tumor effects, highlighting their potential in cancer treatments.
Ribosome-inactivating proteins have been discovered in bacteria, fungi, algae, and plants (RIPs). Because of N-glycosylase activity, RIPs cleavage adenine residues at a conserved site on the 28S rRNA.The cleavage of this single N-glycoside bond inhibits protein synthesis because it interferes with the elongation factors’ ability to associate with the ribosome. MAP30 is an anti-HIV plant protein from bitter melon. It has anti-tumor properties, topological inactivation of viral DNA, suppression of viral integrase, and cell-free ribosome inactivation. Riproximin was used to treat colorectal cancer. Riproximin is isolated from Ximenia Americana which is a type 2 RIP. MAP30 has more therapeutic potential than other RIPs since it is not only effective against HSV and HIV infection and replication, but it is also nontoxic to normal cells. Ribosome-inactivating proteins to obtain resistance against fungal pathogens are based on the ability of some RIPs to depurinate the ribosome of various fungi. Soybean toxin (SBTX) is a toxin produced by soybeans that is harmful to pathogenic fungi and yeast.
No takes yet. Share an insight, caveat, or question.
Supe et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: